Search research articles
Contact Us
Filters
Showing results (31-40 of 61) with videos related to
Page
of 7
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 3, 2017
Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients
Anne-Ségolène Cottereau, Tarec Christoffer El-Galaly, Stéphanie Becker, et al.
Cancers
|
April 12, 2022
Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
Christophe Bonnet, Jehan Dupuis, Hervé Tilly, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 19, 2022
Distinction of Lymphoma from Sarcoidosis on <sup>18</sup>F-FDG PET/CT: Evaluation of Radiomics-Feature-Guided Machine Learning Versus Human Reader Performance
Pierre Lovinfosse, Marta Ferreira, Nadia Withofs, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 18, 2022
Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations
Alina Nicolae, Justine Bouilly, Diane Lara, et al.
Blood Advances
|
April 12, 2021
The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA
Lieselot Buedts, Iwona Wlodarska, Julio Finalet-Ferreiro, et al.
The Lancet. Haematology
|
July 13, 2019
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Franck Morschhauser, Steven Le Gouill, Pierre Feugier, et al.
Eclinicalmedicine
|
April 1, 2025
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
Clémentine Sarkozy, Thierry Jo Molina, Sydney Dubois, et al.
Lancet (London, England)
|
November 29, 2011
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
Christian Récher, Bertrand Coiffier, Corinne Haioun, et al.
Leukemia & Lymphoma
|
April 28, 2016
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies
Sylvain Pilorge, Stephanie Harel, Vincent Ribrag, et al.
Haematologica
|
December 1, 2022
ALK-negative anaplastic large cell lymphoma with <i>DUSP22</i> rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
David Sibon, Bettina Bisig, Christophe Bonnet, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 61) with videos related to
Sort By:
Page
of 7
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 3, 2017
Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients
Anne-Ségolène Cottereau, Tarec Christoffer El-Galaly, Stéphanie Becker, et al.
Cancers
|
April 12, 2022
Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
Christophe Bonnet, Jehan Dupuis, Hervé Tilly, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 19, 2022
Distinction of Lymphoma from Sarcoidosis on <sup>18</sup>F-FDG PET/CT: Evaluation of Radiomics-Feature-Guided Machine Learning Versus Human Reader Performance
Pierre Lovinfosse, Marta Ferreira, Nadia Withofs, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 18, 2022
Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations
Alina Nicolae, Justine Bouilly, Diane Lara, et al.
Blood Advances
|
April 12, 2021
The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA
Lieselot Buedts, Iwona Wlodarska, Julio Finalet-Ferreiro, et al.
The Lancet. Haematology
|
July 13, 2019
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Franck Morschhauser, Steven Le Gouill, Pierre Feugier, et al.
Eclinicalmedicine
|
April 1, 2025
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
Clémentine Sarkozy, Thierry Jo Molina, Sydney Dubois, et al.
Lancet (London, England)
|
November 29, 2011
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
Christian Récher, Bertrand Coiffier, Corinne Haioun, et al.
Leukemia & Lymphoma
|
April 28, 2016
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies
Sylvain Pilorge, Stephanie Harel, Vincent Ribrag, et al.
Haematologica
|
December 1, 2022
ALK-negative anaplastic large cell lymphoma with <i>DUSP22</i> rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
David Sibon, Bettina Bisig, Christophe Bonnet, et al.
Page
of 7